Cowen & Co. Reaffirms Their Buy Rating on Vertex Pharmaceuticals

By Carrie Williams

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (NASDAQ: VRTX) on December 8 and set a price target of $200. The company’s shares closed on Friday at $143.61.

According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 9.8% and a 51.3% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Achillion Pharmaceuticals, and Catabasis Pharmaceuticals.

Vertex Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $181.64.

The company has a one-year high of $167.86 and a one-year low of $71.46. Currently, Vertex Pharmaceuticals has an average volume of 1.53M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington’s disease and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.